

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

ANNOUNCEMENT IN RELATION TO RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, due to other personal work commitments, Ms. Ma Cuifang has resigned as a non-executive director of the Company with effect from September 6, 2021 (the “**Resignation**”).

Ms. Ma Cuifang has confirmed that she has no disagreement with the Board and there is no other matter in relation to the Resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to thank Ms. Ma Cuifang for her valuable contribution to the Company during her tenure of service.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, September 6, 2021

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.